Teva Pharmaceutical Industries Ltd ADR Stock
The Teva Pharmaceutical Industries Ltd ADR stock is trending slightly upwards today, with an increase of €0.10 (0.390%) compared to yesterday's price.
With 17 Buy predictions and not the single Sell prediction the community is currently very high on Teva Pharmaceutical Industries Ltd ADR.
With a target price of 27 € there is a slightly positive potential of 5.88% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 25.5 €.
Our community identified positive and negative aspects for Teva Pharmaceutical Industries Ltd ADR stock for the coming years. 3 users see the criterium "Worthwhile Investment for the next years" as a plus for the Teva Pharmaceutical Industries Ltd ADR stock. On the other hand our users think that "Conscious of the environment" could be a problem in the future.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Cons
?
B****
?
M***** P*******
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | 0.390% | 3.673% | 15.982% | 61.270% | 18.140% | 192.627% | 198.824% |
| Bayer AG ADR | 3.350% | 8.187% | 30.282% | 90.329% | 86.492% | -27.734% | -20.940% |
| Roche Holding AG ADR | -1.300% | 2.864% | 10.156% | 26.398% | 27.949% | 10.236% | 21.155% |
| Astrazeneca ADR | -0.650% | -0.645% | 0.000% | 21.260% | 20.313% | 16.667% | 86.893% |
Comments
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Bank of America Corporation from $29.00 to $32.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $35.00 price target on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $28.00 to $31.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat